Entera Bio board members purchase shares in open market transactions Feb 11, 2026 09:03AM
OPKO Health and Entera Bio expand partnership for oral PTH tablet Feb 4, 2026 08:02AM
Entera Bio outlines Q1 2026 milestones for osteoporosis drug Jan 21, 2026 08:31AM
H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX) Dec 24, 2025 06:44AM
Entera Bio reports preclinical data for once-daily hypoparathyroidism tablet Dec 22, 2025 08:32AM


Nov 14, 2025 05:43PM Entera Bio Ltd. (ENTX) Tops Q3 EPS by 16c
Sep 25, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)
Sep 15, 2025 09:01AM Entera Bio presents oral GLP-2 tablet data at medical conference
Sep 8, 2025 08:32AM Entera Bio presents bone density improvements from EB613 osteoporosis drug
Aug 28, 2025 08:05AM Entera Bio to present clinical data at September medical conferences
Aug 11, 2025 06:42AM Entera Bio Ltd. (ENTX) Tops Q2 EPS by 5c
Jul 8, 2025 08:03AM OPKO Health and Entera Bio abstract selected for ESPEN Congress
Jun 25, 2025 08:05AM OPKO Health (OPK) and Entera Bio (ENTX) Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation
May 30, 2025 04:11PM Entera Bio Ltd. (ENTX) Files $100M Mixed Shelf
May 9, 2025 05:06PM Entera Bio Ltd. (ENTX) Tops Q1 EPS by 1c
Apr 15, 2025 08:32AM Entera Bio Ltd. (ENTX) Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis
Mar 17, 2025 08:01AM OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement
Oct 7, 2024 06:36AM H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)
Sep 27, 2024 06:51AM H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)
Sep 25, 2024 08:31AM Entera Bio Ltd. (ENTX) and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin Peptide Tablet Candidate